Replicor Inc.
Records under this name other than the patents Replicor Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
Showing 1 to 6 of 6 · Back to Replicor Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,616,083 | Oligonucleotide chelate complex methods Lapsed on the fee record Ended Apr 11, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 11, 2025 | From the USPTO record |
| US 9,603,865 | Methods for the Treatment of Hepatitis B and Hepatitis D Virus Infections Lapsed on the fee record Ended Mar 28, 2025 · High confidence | Lapsed on the fee record | Ended Mar 28, 2025 | High confidence |
| US 7,358,068 | Antiviral oligonucleotides Term ended Term ended Oct 18, 2024 · From the USPTO record | Term ended | Term ended Oct 18, 2024 | From the USPTO record |
| US 8,067,385 | Antiviral oligonucleotides targeting HBV Lapsed on the fee record Ended Nov 29, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 29, 2023 | From the USPTO record |
| US 8,008,269 | Antiviral oligonucleotides Lapsed on the fee record Ended Aug 30, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 30, 2023 | From the USPTO record |
| US 8,008,270 | Antiviral oligonucleotides targeting viral families Lapsed on the fee record Ended Aug 30, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 30, 2023 | From the USPTO record |